Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Clolar. Every FDA application for this active ingredient: 1 branded and 13 generic.
As of Nov 14, 2026, FDA lists 14 applications for Clofarabine (sold as Clolar), first approved Dec 28, 2004, with 2 new uses approved and 0 published complete response letters.
First approved: Dec 28, 2004
Applications: 14
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $17K
First approved in the EU: May 29, 2006
First approved in Japan: Mar 25, 2013
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 99 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Evoltra, new ingredientA drug with a new active ingredient for the treatment of recurrent or refractory acute lymphoblastic leukemia. · Genzyme Japan K.K. · Mar 25, 2013
Clinical Trials
19 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Accord Hlthcare
Eugia Pharma
Zydus Pharms USA Inc